Wuxi Vision Pro Raises $12.6 Million in Series B Round

May 4, 2018: By Joan McKenna

China-based Wuxi Vision Pro Ltd. announced May 4 that it has completed a $12.6 million (RMB 80 million) Series B round of financing.

The intraocular lens (IOL) manufacturer said it is committed to developing high-quality products and a leading brand to meet the growing demand for eye care in China, particularly in cataract surgery, where the company said there is huge room for growth.

Investors in the round are Qiming Venture Partners and Ruijian Capital.

Wuxi Vision Pro, founded in 2010, developed its own IOL material, a high refractive index hydrophobic acrylic biocompatible material.

Its Leiming brand aspheric IOL has obtained CFDA approval and CE marking approval.

The company’s facility for lens materials development and manufacturing is located in Irvine, California.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Carl Zeiss Meditec Announces Milestone of 1.5 Million SMILE Procedures

Heidelberg Gains US Clearance for OCT Angiography Module

ASCRS Convenes Task Force to Study CyPass Data, Make Recommendations

Bascom Palmer Treats First US Patient in Nightstar’s Trial for X-Linked Retinitis Pigmentosa

First Patient Treated in Allotex’ Trial for Allogenic Refractive Lenticules for Presbyopia

Bausch + Lomb Announces Positive Results for Loteprednol Etabonate Gel

LumiThera Set to Launch Valeda Light Delivery System for Dry AMD

Kodiak Sciences Names Jason Ehrlich, MD, PhD, Chief Medical Officer

Second Sight Receives $1.6 Million Grant from NIH to Support Orion Program

Regeneron to Invest $800 Million in New York Campus

American Women Raise Funds for Nepal Mission to Reduce Corneal Blindness

Ziemer to Add Lenticule Extraction Capabilities to LDV Z8

Stealth BioTherapeutics Raises $100 Million in Support of Elamipretide for Dry AMD

STAAR Gains US Approval of Visian Toric ICL

Sun Pharma, SPARC Announce FDA Approval for Xelpros for Open-Angle Glaucoma, Ocular Hypertension

FDA Will Review Regeneron’s Submission to Expand Eylea’s Labeling to All DR Patients

Alcon Will Locate Headquarters in Switzerland

Kodiak Sciences Files for $100 Million IPO

Iridex Announces $10 Million Public Offering

Oxford BioMedica Expands Capacity with New Facility